Study of tamoxifen and raloxifene

STAR trial (Study of tamoxifen and raloxifene), which was completed in 2006, demonstrated additional utility of raloxifene in the prevention and treatment of breast cancer. In fact, the absence of associated uterotrophic effects with raloxifene suggests that it may be a safer agent than tamoxifen for use as a chemopreventative in high-risk postmenopausal women [3] therefore, raloxifene has very recently become a new option for breast cancer prevention now available for physicians and their patients. 

Vogel VG, Costantino JP, Wickerham DL, Cronin WM, Wolmark N (2002) The study of tamoxifen and raloxifene preliminary enrollment data from a randomized breast cancer risk reduction trial. Clin Breast Cancer 3 153-159... 

Further demonstration of the utility of raloxifene in the prevention of breast cancer came from the STAR trial (Study of Tamoxifen and Raloxifene), which followed more than 19,000 post-menopausal women for 5 years. This was a prospective, doubleblind, randomized trial comparing 20 mg/day tamoxifen versus 60 mg/day raloxifene, which resulted in the demonstration that incidence rates of invasive breast cancer for both treatments were comparable.39... 

Vogel VG, Costantino JP, Wickerham DL, et al. Effects of tamoxifen vs raloxifene on the risk of developing invasive breast cancer and other disease outcomes the NSABP study of tamoxifen and raloxifene (STAR) P-2 trial. JAMA 2006 295(23) 2727 L... 

To illustrate the different actions of both groups of antiestrogens, Table 6.1 presents the tissue-specific effects obtained with the administration of type I (tamoxifen and raloxifene) and type II (ICI 164384 and fulvestrant) antiestrogens in preclinical studies. 

Zajchowski et al. [107] showed comparison of expression profiles between 38 different estrogen receptor-modulating compounds. An intial study was run based on the results of profiling of 24 combinations of cells and genes with estrogen, tamoxifen, raloxifene and ICI 164384 (a pure ER antagonist). Using the optimized assay panel derived from these studies, the 38 compounds were then profiled and classi-... 

The main source of data for raloxifene derives from the MORE study. A twofold increased risk for VTED was observed through 4 years of followup (Delmas et al. 2002), and, as for HT and tamoxifen, an accumulation of events occurred during the first year. 

---